Bulletin

WHO

WHO Member States agree to share outcomes of historic IHR, pandemic agreement processes to World Health Assembly

May 24, 2024

WHO

WHO releases a strategic framework for enhancing prevention and control of mpox

May 24, 2024

WHO

Shipment of newest malaria vaccine, R21, to Central African Republic marks the latest milestone for child survival

May 24, 2024

WHO

Tobacco and nicotine industry tactics addict youth for life

May 23, 2024

Press Information Bureau

Union Health Secretary addresses High-Level Meeting on “Advancing Health and Well-Being of Billions in WHO South-East Asia Region”

May 22, 2024

Press Information Bureau

In a significant milestone achieved under the National Tele Mental Health Programme of India, the Tele-MANAS Helpline receives over 10 lakh calls since its launch in October 2022

May 22, 2024

Press Information Bureau

In a significant milestone achieved under the National Tele Mental Health Programme of India, the Tele-MANAS Helpline receives over 10 lakh calls since its launch in October 2022

May 22, 2024

WHO

Largest number of regulatory agencies for medical products approved as WHO Listed Authorities

May 20, 2024

Roche

Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer

May 15, 2024

WHO

WHO prequalifies new dengue vaccine

May 15, 2024

Press Information Bureau

Secretary, Department of Pharmaceuticals launches the MEDITECH STACKATHON 2024 in collaboration with CII at New Delhi

May 7, 2024

WHO

Governments near agreement on package of amendments to the International Health Regulations (2005)

April 28, 2024

WHO

Major step in malaria prevention as three West African countries roll out vaccine

April 25, 2024

Roche

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

April 19, 2024

Roche

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

April 17, 2024

Roche

Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study

April 15, 2024

< 1 … 28 29 30 31 32 33 34 35 36 … 94 >

Bulletin

WHO Member States agree to share outcomes of historic IHR, pandemic agreement processes to World Health Assembly

WHO releases a strategic framework for enhancing prevention and control of mpox

Shipment of newest malaria vaccine, R21, to Central African Republic marks the latest milestone for child survival

Tobacco and nicotine industry tactics addict youth for life

Union Health Secretary addresses High-Level Meeting on “Advancing Health and Well-Being of Billions in WHO South-East Asia Region”

In a significant milestone achieved under the National Tele Mental Health Programme of India, the Tele-MANAS Helpline receives over 10 lakh calls since its launch in October 2022

In a significant milestone achieved under the National Tele Mental Health Programme of India, the Tele-MANAS Helpline receives over 10 lakh calls since its launch in October 2022

Largest number of regulatory agencies for medical products approved as WHO Listed Authorities

Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer

WHO prequalifies new dengue vaccine

Secretary, Department of Pharmaceuticals launches the MEDITECH STACKATHON 2024 in collaboration with CII at New Delhi

Governments near agreement on package of amendments to the International Health Regulations (2005)

Major step in malaria prevention as three West African countries roll out vaccine

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study

Company

Resources